CoChat

Abstract 12007: Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography: A Randomized Controlled Trial

Ando, Kaoru, Watanabe, Tetsu, Daidoji, Hyuma, Otaki, Yoichiro, Hashimoto, Naoto, Kumagai, Yu, Hashimoto, Naoaki, Narumi, Taro, Kadowaki, Shinpei, Yamaura, Gensai, Wanezaki, Masahiro, Funayama, Akira, Yashiro, Yoshinori, Iwayama, Tadateru, Nishiyama, Satoshi, Takahashi, Hiroki, Arimoto, Takanori, Shishido, Tetsuro, Miyamoto, Takuya, Kubota, Isao · 2015 · Circulation
Cited by 16

The DOI matches its Crossref record.

Abstract

Introduction: High intensity statin therapy is established for secondary prevention of coronary heart disease (CHD). However, additional therapy is required to reduce residual risk in CHD patients with aggressive lipid-lowering therapy. Eicosapentaenoic acid (EPA) was reported to be beneficial especially in secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by additional administration of EPA to high dose pitavastatin (PTV) therapy. Methods: We enrolled 200 CHD patients who underwent percutaneous coronary intervention in 6 hospitals. Patients were randomly allocated to PTV group (PTV 4 mg/day, n=98) and PTV/EPA group (PTV 4 mg/day and EPA 1800 mg/day, n=102), and prospectively followed for 6 to 8 months. Coronary plaque volume and composition in non-stenting lesion were analyzed by integrated backscatter intravascular ultrasonography at baseline and follow up. Results: EPA / arachidonic acid (AA) ratio was significantly increased in PTV/EPA group compared to PTV group at follow up period. Plaque volume and lipid volume were significantly reduced in PTV/EPA group, but not PTV group. There was a significant inverse correlation between change in EPA/AA ratio and changes in plaque volume (r=-0.332, p<0.001). Plaque regression was defined as percent change in plaque volume more than -14.6% according to previous reports. A multivariate logistic analysis demonstrated that the additional administration of EPA was independently associated with plaque regression after adjustment of confounding factors. The prevalence rate of plaque regression was significantly higher in PTV/EPA group than in PTV group (50% vs. 24%, p<0.001). Conclusions: Additional administration of EPA to high dose PTV therapy significantly reduced coronary plaque volume, suggesting that combination therapy of EPA and PTV might reduce residual risk in CHD patients with aggressive lipid-lowering therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circ.132.suppl_3.12007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Ando, K., Watanabe, T., Daidoji, H., Otaki, Y., Hashimoto, N., Kumagai, Y., Hashimoto, N., Narumi, T., Kadowaki, S., Yamaura, G., Wanezaki, M., Funayama, A., Yashiro, Y., Iwayama, T., Nishiyama, S., Takahashi, H., Arimoto, T., Shishido, T., Miyamoto, T., & Kubota, I.
Venue
Circulation
Published
2015-11-10
Volume
132
Issue
suppl_3
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2345269362
Cited by
16
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract 12007: Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1161/circ.132.suppl_3.12007
The paper
Ando, K., Watanabe, T., Daidoji, H., Otaki, Y., Hashimoto, N., Kumagai, Y., Hashimoto, N., Narumi, T., Kadowaki, S., Yamaura, G., Wanezaki, M., Funayama, A., Yashiro, Y., Iwayama, T., Nishiyama, S., Takahashi, H., Arimoto, T., Shishido, T., Miyamoto, T., & Kubota, I. (2015). Abstract 12007: Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography: A Randomized Controlled Trial. Circulation. https://doi.org/10.1161/circ.132.suppl_3.12007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.